Investing
Brean Murray Comments on Dendreon (DNDN) Following Friday's Run-Up
Published:
Last Updated:
Brean Murray comments on Dendreon (Nasdaq: DNDN) this morning, following Friday’s 38% run-up, which they said was related to competitor’s call with a physician in the field and word Provenge Phase 3 trial results being slated for potential presentation on April 28 at the American Urological Association annual meeting. Brean Murray said neither of these changes anything fundamental about the trial outcome.
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.